Nearly half of uncontrolled hypertensive patients could be controlled by high-dose titration of amlodipine in the clinical setting: The ACHIEVE study

Current Hypertension Reviews

Volumn 7, Issue 2, 2011, Pages 102-110

  Kario, Kazuomi ^a   Odawara, Masato ^b   Kimura, Kenjiro ^c   Node, Koichi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAGA UNIVERSITY   (Japan)

Author keywords

Amlodipine; Clinic blood pressure; Home blood pressure; Up titration

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

EID: 80053468618     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340211797457872     Document Type: Article

References (9)

1. ALLHAT collaborative research group. Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) JAMA 2002; 288: 2981-2997.
2. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022-2031.
3. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus aterolol adding bend of umethia zide as reguire in the Anglo-Scandinavian cardiac outcomes trial - blood pressure lowering arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.
4. Jamerson KJ, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428.
5. Fujiwara T, Ii Y, Hatsuzawa J, et al. The phase III, double-blind, parallel-group controlled study of amlodipine 10 mg once daily in Japanese patients with essential hypertension who insufficiently responded to amlodipine 5mg once daily. J Hum Hypertens 2009; 23: 521-529.
6. Ki Kuchi K, Matosuoka H, Ogihara T, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.
7. Eguchi K, Kario K, Shimada K. Effects of long-acting ACE inhibitor (temocapril) and long-acting Ca channel blocker (amlodipine) on 24-h ambulatory BP in elderly hypertensive patients. J Hum Hypertens 2001; 15: 643-648.
8. ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585.
9. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304: 61-68.